Logo Image
News|Articles|August 23, 2023

Indegene Launches Invisage, a New Omnichannel Sales and Marketing Platform

Program designed to aid life science organizations in improving go-to-market strategy.

Indegene has officially launched Invisage, its new sales and marketing program. Aimed at helping life science companies optimize their go-to-market models, the technology reportedly delivers personalized outcomes to healthcare professionals (HCPs) by leveraging data from over two million HCPs with over 200 million interactions.

Indegene describes Invisage as an integrated hybrid omnichannel platform that combines data, AI-driven scientific modeling, and strategic insights to deploy digital campaigns and partner digital channels with a sales force to expand HCP reach and optimize interactions.

“We are excited to introduce Invisage to the market and enable life sciences companies to effectively reach HCPs, powered by Indegene’s AI-driven platform and our team of experts,” said Nancy Phelan, SVP, omnichannel activation, Indegene. “Invisage paves the way for companies to seamlessly transition to and sustain a hybrid model, knowing that this modern approach can provide HCPs the personalized information they need to deliver improved patient outcomes.”

Reference: Indegene launches Invisage, an AI-enabled hybrid omnichannel sales and marketing platform to improve HCP impact for life sciences companies. GlobNewswire. August 22, 2023. Accessed August 23, 2023. https://www.globenewswire.com/news-release/2023/08/22/2729333/0/en/Indegene-launches-Invisage-an-AI-enabled-hybrid-omnichannel-sales-and-marketing-platform-to-improve-HCP-impact-for-life-sciences-companies.html

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
Read more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more